Theriva Biologics will present additional data from its Phase 2b VIRAGE clinical trial of VCN-01 combined with chemotherapy for metastatic pancreatic cancer at the AACR 2026 Annual Meeting. The data show immune-mediated action of VCN-01 and improved patient outcomes, including longer response duration and survival in multiple subgroups. Theriva has agreements with FDA and EMA to proceed with a pivotal Phase 3 trial and plans further studies to optimize dosing. This development highlights potential new treatment options for a cancer with poor prognosis and limited therapies.
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Red Light Holland, after acquiring Filament Health, has expanded its capabilities in pharmaceutical-grade psilocybin development. Filament completed a shipment of its botanical psilocybin drug candidate, PEX010, to the European Union to support multi...
